Skip to main content

Pharvaris N.V Investor Event Transcript, Nov 9, 2026

Pharvaris N.V. (PHVS)

Pharvaris N.V. has an April 23rd, 2027 PDUFA date for on-demand treatment, plans CREATE topline data in the first quarter of next year, and expects parallel prophylaxis NDAs after collecting safety data in the first half of the 27th year. AI summary

Investor Event Transcript 2026-11-09 For: 2026-12-31
Added on November 09, 2026

Conference Transcript - PHVS 2026-11-09

Devjit, Analyst

Good afternoon, and thank you for joining Guggenheim's third annual Health Care Innovations Conference. I am Devjit, one of the therapeutic analysts, and joining me on stage are Pong Liu, president, and Maggie Beller, the head of IR for Varus. Thank you both for making time for us.

Maggie Beller, Head of Investor Relations

Thanks for having us.

Devjit, Analyst

So who wants to take the first one? Maybe for people who have not heard the story, a very quick intro would be helpful, and then we can dive into the Q&A.

Peng Lu, Other

Yeah, maybe I can start. I'm Peng Lu here. I'm the president of Favars. Actually, I'm a physician scientist. I've been working in HE over a decade, and always our, you know, motivation is how we can translate the novel science to really help the patients and really address what the patients need. That's exactly why we built up Favars here. For us, actually, it's a company really dedicated to developing oral treatment that for HE or maybe potentially breadcrumbs, you know, immediate patients there. Currently, we have our leading compound, the diocritibane, and have one molecule with two different formulations. One formulation absorbed in upper GI and would be considered for on-demand treatment to help the HE patients. And the other is the prophylactic formulation, and to be considered for the, you know, the prevention of the, you know, attacks for the HEO, eventually, for the bright kidney, median angioedema patients. Currently, indeed, in the exciting moment set for the company, and we are very closing to bring Dukritvan for our patients to give them greater control and simplicity here.

Maggie Beller, Head of Investor Relations

Yep, and just a quick update across the business. We read out our pivotal phase three on-demand data in December of last year. We have a PIDUFA date for that on April 23rd, 2027. That will be for decreed demand for the on-demand treatment of HAE attacks. Additionally, we just read out our pivotal chapter three prophylactic data in September of this year. And we are on track to submit an NDA for that. As Pung mentioned, we're hoping to submit it for bradykinin-mediated angioedema because we're also going to be reading out top-line data from our CREATE study, which is the do correct demand for the prevention of acquired angioedema attacks. That'll be in the first quarter of next year. So lots of really exciting things happening for Favaris right now.

Devjit, Analyst

So let's unpack that a little bit, the create data. If that reads out positively, you are going to wait for that data before you submit the NDA for decryptivant for- And do you click demand XR, right?

Maggie Beller, Head of Investor Relations

So the rate-limiting step for the NDA is actually our open label extension data, the safety database from Chapter 4. It happens to be that the CREATE data will align with our timing for the submission of the HAE NDA. So by combining the AAE data set with our HAE data set, we can actually apply for a broader label of bradykine-mediated angiotema, and that may open us up to priority review.

Devjit, Analyst

So that's what I was going to get at. How important are the CREAT data for a priority review versus a standard review?

Peng Lu, Other

Yeah, maybe I can help address it. Currently both that our chapter 4 study and CREAT study, as Maggie introduced, on track here, that we expect we will move forward at a very simultaneous time. But as mentioned, there is no bonding together here. That no matter for HE or, you know, create that acquired angio-dema study is we are discussing with the agency. But as Maggie mentioned, for the Ducritban, especially for our prophylaxis treatment, that acquired patients, they have no any treatment available. From the whole community, they have strong desire for the treatment available for them. That's exactly what we try all the best to give these patients, you know, the available treatment as soon as possible. That's why we target to submit both HE and acquired angioedema in parallel at the same time. For breast kidney median angioedema, the more broad umbrella term here.

Devjit, Analyst

Got it. There is not much of a clinical debate right now, given that the Chapter 3 had injectable-like efficacy for an oral product. But how are you guys internally thinking about the commercial landscape, given that this is a complicated, or not complicated, but it's a crowded commercial landscape, right? So how are you thinking about what could happen, say, 12 months from now?

Peng Lu, Other

Actually, maybe I can start here. That's definitely that currently, as mentioned, the next year is incredibly exciting for us. And currently that we have built up that the commercial team, especially U.S. commercial team, as mentioned, that's a highly competitive field. And, but meanwhile, we have very strong team and have that no matter for our R&D team and the commercial team have deep root in the aging field, have very good connection with the whole community and also with the patient advocacy group here. Therefore, so far, we are very proud, right? We have almost 80, 90 percent commercial team on board, and we are quite ready that to move towards that the, you know, that our get knock on wood, get the pullover. Let it get approval in the U.S. in April next year and get a strong launch there.

Maggie Beller, Head of Investor Relations

Maybe I can add a little bit just to the dynamics between some of the competitors in this space. So, in the on-demand side of the business, we really feel that orals will dominate, seeing as you need to treat an attack after it happens to be able to address the signs and symptoms. The decreased treatment burden that one has when treating with an oral as opposed to an injectable is highly, it highly prefers an oral because it's just easier to take. It's more discreet. The current injections sting when you have to inject them. And one of the things that Ducryctobant brings to the table is that it utilizes the same mechanism of action as a Catobant, which is the most widely used on-demand therapy right now. So what we view it as is a B2 receptor antagonist just like a Catabant, but this time oral. So that's really where we see the on-demand shaking out is that orals will dominate, and we have the benefit of the same mechanism. With prophylaxis, we think that there are likely going to be a winner in the oral space and a winner in the injectable space. This is the benefit of having multiple therapies that are approved, is that each patient and physician can select what is best for that person's life. As you mentioned before, we're showing injectable-like efficacy. So for the first time, people aren't needing to make a decision between their efficacy, their tolerability, and their convenience. So somebody can prefer an oral, or they may prefer an injectable, but now for the first time with our Chapter 3 data, they don't have to forego efficacy to have the convenience of an oral.

Devjit, Analyst

Got it. So on the Chapter 3, when you think about the baseline, the attack rate at baseline was relatively high compared to some of the other studies. When you look through your data, does the efficacy hold up across patients with... Higher baseline attack rates versus those with lower.

Peng Lu, Other

Yeah, actually, that's a very interesting question that here that I understand that people ask us, right, why is the baseline that attack rate is high 3.6, something like that, because for baseline, actually, there is a running period. It's a very short period compared to the general screening period in the past for phase two study. If we look at the other pivotal study, as you look at it here, that no matter for the Donald Dorsen or the Mosey Z or even Texaro around that time, or the baseline attack rate, It's around a similar range. It's between 3.5 to 3.6. As I mentioned, if we look at the placebo group, that for the chapter 3 study, it's also around the two attacks per month. It's very comparable across all the other pivotal trials. Therefore, overall, the chapter 3, the patient segmentation, And I think it's a very, you know, that quite, you know, similar to other pivotal trial there. And also, as Maggie mentioned, it really reflects that, you know, duCritiband, that for prophylactic treatment effect is comparable to injectable.

Devjit, Analyst

Got it. Now, on the safety side, there were obviously those two patients with grade 3 liver enzyme elevations. It's pretty well explained, one with fatty liver disease, the other with prior anabolic treatment. How do you think FDA is going to handle those?

Peng Lu, Other

Yeah, I can take it here that, as Maggie mentioned here, that, you know, for the currently, there's a profit market here, right, that a patient really prefers the oral treatment with injectable-like efficacy, but there is no sacrifice for safety part. As we always discuss here, that for the Ducrepan, no matter for the chapter one, that we just published our long-term safety data, and also the chapter three we just released here, That Ducritabin was very well tolerated. There are indeed that two, that level two, that liver enzyme elevation, we shared during the public, you know, top-line readout there. Actually, that for the HE patients, that due to the C1, that, you know, Serpene 1 gene mutation, C1 deficiency, that the patients have fragile liver. Therefore, liver enzyme elevation as a background to the disease there is not rare. Meanwhile, all these patients have that long-term, especially for international ex-US patients, they have long-term androgen use and also have the concomit, some, for example, fatty liver and all the disease there. Therefore, we can tell almost for every prophylactic, you know, treatment trial there, there is a liver enzyme elevation reported.

Devjit, Analyst

So, do you have a sense of what percentage of patients in the United States are on danazole, if any, at this point, given all the options, and also on a fatty liver side, do you have a sense of what these numbers could be from an exclusion perspective?

Peng Lu, Other

Yeah, currently, the danazole use that in U.S., because all the modern therapy available is very low now, pretty much, I think, less than 5% of U.S. patients still on danazole use. There is some patients still stick on denazole, but less and less here. But compared to international or ex-US, this number is much higher. Especially, for example, for the Chapter 3 trial, we include patients from Latin American countries, from Asian Pacific countries. These countries' denazole use is maybe still 20 to 30 percent.

Devjit, Analyst

Got it. And beyond the two patients, the rest of the safety profile was clean, right? There were no other... Call it grade 1, 2, liver enzyme elevations.

Peng Lu, Other

Actually, I have to say that as overall, that is a liver enzyme, the lab abnormality part for the chapter 3 trial is very comparable or within the range to other prophylax treatment trial there.

Maggie Beller, Head of Investor Relations

I'd also add that one of the things we were really proud to see was very clean safety from a cardiovascular perspective and also from a GI side effect perspective. So those were two things that we were focused on because of just other discussions that have been going on in the KOL space and the other approved orals. We really wanted to make sure to demonstrate to CricktoBand's generally well-tolerated profile, and we were happy to see that with the data across the board.

Devjit, Analyst

And what do you need to see from the Chapter 4 safety database? And do you have insights into how that's playing out right now?

Peng Lu, Other

Yes, that's typically very standard for all the HE treatment developments. Typically, the agency would expect one-year safety data. That's exactly, as Maggie at the beginning mentioned, currently a critical path for our NDA filing for prophylaxis actually is the long-term safety package there. We expect we collect all the data, the first half of the 27th year, then we can submit that, you know, the NDA filing for the prophylaxis. Meanwhile, for the acquired angiodema, as we mentioned, they only need the ethics data because the safety data, we will leverage that as a safety package for each That's the whole that our development strategy and the filing strategy, how we can use that as a parallel, that the development here, that is a totality of package and the target for broader indication.

Devjit, Analyst

Got it. So let's fast forward, call it 24 months from now, when both of these are in the market. What's the low-hanging fruit commercially? Is it the patients who are on Orlodeo, given that's about a 47% response rate at best? Do you try to switch those, or are you going after Tuxiro because of the injection site issues and all that, or the painful infusions?

Peng Lu, Other

Yeah, actually, Maggie have already mentioned here that currently, I think, no matter from the, you know, that Ordello or that, you know, Act Early Launch, they've already confirmed that the whole community desire for oral treatment. Therefore, I just say that I don't know whether it's, you know, that the low-hanging fruit or not, but around that time, when we consider Ducridban, we really, that the development of this treatment for all the HE patients who prefer oral, that options are Oral treatment with injectable-like efficacy. Therefore, as I mentioned, typically, we have designed that strategy for different segments of the patients, but meanwhile, we can tell, right, that for the new patient, it's definitely the patients that they will, for oral treatment, it's easy for them to take and to see that how about their treatment effect. Of course, the patients in the past use oral prophylaxis, but not satisfied for efficacy or safety is also our target patient population, or even current that oral treatment patient, they maybe prefer that a better efficacy and or that injectable like the patients that they are tired of it and also consider oral treatment. All these I have to say that hopefully that can help them.

Devjit, Analyst

Got it. With the IR approval coming up next year, are there any outstanding questions with respect to, with the FDA? And how do you think the label discussions are going to shape up there?

Maggie Beller, Head of Investor Relations

We haven't gotten into the details of how our regulatory interactions are proceeding. We've passed through our mid-cycle review, and all of the activities that should and will and are happening are continuing to progress as planned. So we're really pleased with the engagements that we've had with regulators. For us, when we think about the label overall, we are really interested in having three key points included in the label. And how this exactly works out, we obviously need to wait and have discussions with regulators. But for us, we believe that decreed demands differentiators include its rapid onset of action. So if that's demonstrated either through our primary endpoint of 1.28 hours or a new endpoint of end of progression that we included in our pivotal phase three, that is going to be an important aspect of our label. We also are really proud of our complete symptom resolution. As a reminder, we were able to show that endpoint in less than 12 hours. So the fact that 12 hours after taking Ducryctoban, people had no more signs of their HAE attack. And then the third really important aspect here is the single-dose resolution. So in our study, 83% of people were able to achieve their endpoint with a single dose of Ducryctoban. So those three key aspects, rapid onset of action, complete symptom resolution, and single-dose durability are really important for us in the label. And however that ends up, you know, being built in, we have 11 key secondary endpoints that we achieved. So we're excited to have conversations with regulators about how we're able to demonstrate the differentiation of due correct demand.

Devjit, Analyst

So let's talk about that 83% of the patients having attack resolution with a single dose. Compare that with ectorily. How is that conversation going with pairs? Because that's an interesting item from a differentiation perspective commercially.

Peng Lu, Other

Yeah, actually, that our, you know, that strength of the data, as Maggie just illustrated, and our initial interaction with the U.S. peers are very, you know, positive. I have to say that from the peer side, from the patient side, you can tell that there's a fast onset. It's definitely a key attribute. But meanwhile, from the peer perspective, that a high percentage of attack can treat it with a single dose is very attractive, especially compared to You act early, right? It's around, I believe, that 38% or 39% of tech, they need the second dose, and the even higher percentage of iCataban use a second dose here. If we integrate all together here, that from the peer perspective, you can see it's not only help the patient, but it can help economic side.

Devjit, Analyst

Got it. So... Along those lines, then, do you think you would price it in line with where everybody else is, or is there a premium to be had given the 83% or given the 17% versus 39% delta?

Maggie Beller, Head of Investor Relations

So I think when we, it's premature to get into the nitty-gritty details of our pricing strategy, but we're pleased to see that the pricing corridors within both on-demand and prophylaxis remain very compelling. For example, ectorily right now is about 17,800 per dose. We, however, have the benefit of having an on-demand option and a prophylactic option. So instead of just looking at this and maximizing the cost of one singular asset, we are looking at the portfolio holistically and understanding the levers that need to be pushed or pulled to be able to maximize the value of the portfolio. So, we have the benefit of having really strong clinical data and very proactive payer engagements to be able to have those conversations to be creative with our pricing strategy.

Peng Lu, Other

Absolutely. As Maggie mentioned, we have pipeline within the molecule that we have both an on-demand and a profit discussion with the pairs ongoing. They definitely give us multiple options regarding the pricing part. But meanwhile, fundamentally, I have to say our market assess strategy is to how patients can access Dukritvan as rapid as possible, not only from pricing part, but also from, for example, the quick start sampling and also the contracting, all the different strategies. That's the whole goal for our market assess group.

Devjit, Analyst

Got it. And currently, what is that, like 80% of the market is United States? From a global sales perspective? Absolutely. So what's the strategy for XUS for you guys?

Peng Lu, Other

Yeah, ex-US is definitely a very interesting topic and a lot of discussion with the country, all the geographic, right, that's a policy and the different factors. Currently, I think that our priority is a US launch and for both on-demand and profit, but we do have a lot of discussion for international and for ex-US that we also prioritize maybe in Japan and also that The European countries, but currently, we don't have the details to share yet, but with the Decredible launch next year, we will gradually share more about our launch plan for international of XUS.

Devjit, Analyst

Do you want to build an organization for XUS, or would this be a good, non-dilutive funding opportunity for the company? Go ahead.

Maggie Beller, Head of Investor Relations

These are options that are on the table right Right now, we haven't committed to an ex-US strategy, but I think importantly, we are also not hindering our ability to be able to move forward with an ex-US launch, whether it's by us, by a partner, or somebody else. Our MAA is validated and under review right now. We have a plan for other regulatory bodies throughout the globe, so we haven't committed to a strategy yet.

Devjit, Analyst

Got it. Can you just walk me through your final headcount on the commercial side as you sort of prepare for the launch next year and then the one year after?

Peng Lu, Other

Yeah, currently, as I mentioned at the beginning, that we are almost there to wrap up that the commercial team built up, and currently we target maybe very in line with the competitive benchmark here. I believe we shared in the past that we target maybe 80 to 90 percent, 80 to 90 team members for U.S. commercial teams, that's including also the medical there. We have pretty much 90 percent team ready on board.

Maggie Beller, Head of Investor Relations

Like, 30 to 40 of those people will likely be sales reps.

Devjit, Analyst

And the number that you are sort of, or the allergists and physicians you're targeting is about 2,500. It's from what I remember from my other companies.

Maggie Beller, Head of Investor Relations

Yep, that's exactly right.

Devjit, Analyst

Got it. Awesome. Well, looking forward to a very compelling 2027 for you guys, and thank you for making time for us.

Maggie Beller, Head of Investor Relations

Thanks so much, Jajit. We really appreciate it.

Devjit, Analyst

Appreciate it. Thank you.

Peng Lu, Other

Thanks, everyone. Thank you.